Safety and Effectiveness of Regorafenib

Neoplasms Clinical Trial

— Correlate  

Official title:

Correlate - Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02042144
• Other study ID #: 16821
• Secondary ID: SV1302
• Status: Completed
• Phase: N/A
• First received: January 20, 2014
• Last updated: January 12, 2018
• Start date: April 8, 2014
• Est. completion date: November 10, 2017

Study information

• Verified date: January 2018
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is a prospective observational cohort study. The study will be conducted in routine clinical practice settings. It is planned to enroll 1000 patients with metastatic Colorectal Cancer (mCRC) who have been previously treated with other approved treatments for metastatic disease and for whom a decision has been made by the physician to treat with regorafenib according to local health authority approved label. It is the aim of this observational cohort study to further characterize safety and effectiveness of regorafenib in routine clinical practice setting. Healthcare resource utilization in the routine provision of care is becoming increasingly important from a health economics and outcomes research perspective. Therefore, another aim of this observational cohort study is to capture healthcare resource associated with the management of treatment emergent adverse events in the real world setting. The primary objective of this study is to further characterize safety of regorafenib use in routine clinical practice settings. The secondary objective of this study is to assess the effectiveness of regorafenib in routine clinical practice settings as measured by Overall Survival (OS), Progression Free Survival (PFS) and Disease control rate (DCR). Health Related Quality of Life (HRQoL) Data will be collected in applicable countries.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1034
• Est. completion date: November 10, 2017
• Est. primary completion date: August 19, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib.

Exclusion Criteria:

• Patients participating in an investigational program with interventions outside of routine clinical practice

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• Stivarga (Regorafenib, BAY73-4506)
Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Countries where clinical trial is conducted

Argentina,  Austria,  Czechia,  Denmark,  France,  Italy,  Luxembourg,  Mexico,  Netherlands,  Singapore,  Spain,  Switzerland,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of all treatment-emergent adverse events (TEAE) - Patients will be monitored for TEAE using the NCI-CTCAE Version 4.3		Up to 42 months
Secondary	Overall Survival (OS), OS is defined as the time interval from the start of regorafenib therapy to death, due to any cause.		Up to 42 months
Secondary	Progression free survival (PFS) is defined as the time interval measured from the day of start with regorafenib treatment to (radiological or clinical) progression or death, whichever comes first.		Up to 42 months
Secondary	Disease control rate (DCR) - DCR is defined as percentage of patients, whose best response was not progressive disease (i.e. CR, PR or SD). Stable disease must be at least 6 weeks in duration.		Up to 42 months
Secondary	Quality of Life - HRQoL using PRO questionnaire EQ-5D (8) in applicable countries		Up to 42 months
Secondary	Healthcare resource utilization	Hospitalization (Date, Length), Concomitant medication and procedures and any other anticancer therapies	Up to 42 months

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.